Veeva Systems, California-based with a strong Philly presence, racked up another strong quarter in its FY 20200 3rd quarter. Veeva provides integrated cloud computing services to the Life Sciences industry.
Third-quarter adjusted earnings of 60 cents a share topped analysts’ forecasts by 6 cents, while revenue of nearly $281 million also came in higher than expectations.
The company said it expects fiscal-year adjusted earnings of $2.16 to $2.17 a share, up from its previous outlook of $2.11 to $2.13.
Veeva expects revenue for the fiscal year of about $1.09 billion vs. previous guidance of $1.06 billion to $1.07 billion.
The stock has gained more than 78% so far in 2019.
Veeva’s market capitalization is now $22.3 billion. It has about 3000 employees.
Veeva cited “outperformance in both Veeva Commercial Cloud and Veeva Vault” product lines”. Veeva Vault CDMS is now rolling out in a large-scale Phase 3 trial for more than 12,000 patients across 700 sites and 32 countries, the company says.
Veeva also added two acquisitions in the quarter: Crossix and Physicians World. The financial impact of these two deals to Veeva’s 4th quarter is expected to be total revenues between $13 and $15 million and a non-GAAP operating loss of $6 million.
Physicians World is a platform for Pharma events. Outsourcing_Pharma says Veeva paid about $40 million for it. Crossix is a leader in privacy-safe patient data and analytics.
Propelify founder Aaron Price and Boxed CEO CHIEH HUANG at Propelify 2019 | Malka Media for Propelify
Rather surprisingly, not many hands went up at the fireside chat with the CEO of Boxed (New York) when the audience was asked how many of them had heard of the company. Perhaps it was the cold, breezy and wet weather at Propelify, on the Hoboken waterfront, that had many attendees struggling for ways to keep their hands warm, including keeping them in their pockets.
To Chieh Huang, the upbeat CEO who cofounded the online and mobile, membership-free retailer of bulk-sized packages in an Edison garage in 2013, the lack of recognition was no cause for concern. Rather, it was an indication that there’s plenty of scope for further success at this largely under-the-radar “unicorn.” In addition to its burgeoning B2B and B2C shipping operations, currently serving the lower 48 states, Boxed also manufactures and licenses its own line of warehouse robotics equipment, which is sold or leased to noncompeting international customers. When asked about overseas expansion opportunities by Aaron Price, Propelify founder and recently appointed president/CEO of the New Jersey Tech Council, Huang indicated that there is still ample potential for expansion within the U.S.
The company had humble beginnings, generating about $40,000 in revenue during its first year, but it has certainly come a long way since then. “It is not that sexy to be selling toilet paper out of your garage, and having your own kids and friends rip you for it,” Huang recalled. Even today, his parents ask him when he’ll find a real job. While some family members and friends surreptitiously check out what’s in your medicine cabinet, Huang is more likely to be found inspecting what brand of toilet paper you have on hand. Hopefully, it’s the Boxed house brand, Prince & Spring, creatively named after two streets near the company’s offices.
Boxed also maintains a large warehouse and fulfillment center on our side of the Hudson — in Union, alongside Route 78. Still privately held, the company generated hundreds of millions of dollars in sales during its most recent trailing 12-month period. Moreover, Huang said that Boxed is hiring, with an ongoing need for engineers, tech professionals, marketers, product designers and UX experts. During the fireside chat, he noted that approximately one-third of the employees at the New York offices are relatively recent hires. This means that Boxed faces the same challenge as most businesses: managing growth while striving to keep the corporate culture intact. Huang said that one of his keys to success has been the hiring of some very experienced executives for critical roles in the company. He also candidly confessed that he has a “no A-hole policy.”
Keeping good employees is a priority. Boxed has achieved this by offering such benefits as free healthcare and retirement fund planning. There is also a $500 emergency fund for each employee; approximately 13 percent of Boxed workers have taken advantage of this unique perk. In terms of potentially competing with Amazon as an “everything store” in the e-commerce space, that is not a realistic goal for Boxed, or for any other company, Huang admitted. “That race has already been won,” he said. “It’s like trying to beat Usain Bolt in a 100-meter race. … You’re not going to be able to do it.” Huang expects Amazon to remain a formidable competitor for years to come, or at least until Jeff Bezos decides to step down. Instead, you need to go after specific verticals. For instance, the Prince & Spring house brand has been helping to drive loyalty. A focus on the end customers, and what pain point you’re helping them solve, should be your main goal.
Boxed first acquired outside investment in late 2013, so the company knows that professional investors are unlikely to want to stick around forever without some type of monetizing event or exit. Huang hopes that Boxed can remain an independent company; and, as of now, he believes that he is the right choice to remain at the helm and lead it forward. What advice does he have for fellow founders and entrepreneurs? Try to stay level-headed and avoid emotional roller coasters. “I used to get very high or very low,” he recalled. Also, work to streamline the linear processes within your organization, he suggested
Rob Rinderman is a contributor to NJTechWeekly
I’ve been wondering for some time whether Salesforce’s (NYSE: CRM) growth would falter, but it really hasn’t yet in a big way. Though a string of acquisitions have had a dilutive effect, investors have rewarded it with a growth premium in terms of a higher Price to Earnings (PE) ratio. Its somewhat akin to what happened last year when Netflix briefly surpassed Comcast in market value. Such a PE advantage, though tenuous, gives Salesforce a strong currency for acquiring others.
Salesforce may be on the verge of becoming a more powerful enterprise player than the possibly capital-constrained SAP, under pressure from an activist investor, in spite of its considerably smaller revenue & profit base.
Comparative share prices: Salesforce (light blue) vs SAP (dark blue) Past 5 years
|CRM Mkt cap||$146.8B|
|SAP SE Mkt cap||$162.4B|
In 2018, SAP redesigned & retargeted its CRM, but its way too early to measure how effective that relaunch has been.
SAP CRX ( Qualtrics): The acquisition of Qualtrics opens up an adjacent market to CRM that Salesforce isn’t much of a player in today.
Salesforce could move more into SAP’s space:
- Buying WorkDay would appear financially feasible, though WDAY founders control voting stock (they won’t allow another Peoplesoft). WDAY brings Financial ERP as well as HCM.
- Continue partnerships or consolidate RootStock & Financial Force (manufacturing & financial ERP)
- Buy Zoho if available. Threat to cannibalize Salesforce’s own core business, but could be like Microsoft’s Great Plains acquisition
Salesforce acquisition target list leaked in 2016 – What’s happened since
Adobe Mkt cap 134.91B, essentially the same as CRM
LinkedIn . Acquired by MSFT for $26.2 billion
Workday . Mkt Cap $39.9 billion
ServiceNow . Mkt Cap $50.8 billion
Netsuite . Acquired by Oracle for ~$9.3 billion
Tableau Acquired by Salesforce for $15.7 billion
Pegasystems . Mkt Cap $5.7 billion
Qlik Acquired by Thoma Bravo for $3 billion
Veeva . Mkt Cap $21.7 billion
Box . Mkt Cap $2.6 billion; Recent activist stake
Demandware . Acquired by Salesforce for $2.8 billion
Zendesk Mkt Cap $8.6 billion
Marketo Acquired by Adobe for $4.8 billion
Hubspot . Mkt Cap $6.8 billion
Salesforce’s Mulesoft acquisition last year was totally off the chart. SAP owns no equivalent.
Salesforce needs to decide whether to build a strategy around smaller customers, or double down on larger customers.
Salesforce is also likely looking at ways to accelerate its CRX ambitions.
Another possibility is a dead stop to Salesforce’s organic growth, but that seems unlikely given the size and projected growth of the market
Not discounting Oracle at all, but see it more as a hard engineering company, inconsistent in end user applications.
- Radnor’s CaBaletta, Philly’s latest Biotech star, files for $100 million IPO. CaBaletta is a clinical-stage developer of treatments for autoimmune diseases.
- From Philly JoeD: Dogfight over: Petplan sold to a new private equity owner; dueling owners exit dueling owners settle and exit
- Boomi kicks off Fall Show with new branding
- Boomi Partners with Accenture to Introduce Conversational AI Solutions
- Does the latest Boomi news position it as Dell’s next rising star?
- Health care startup TrekIT gets new CEO, funding #McCorkle moves on .
Colorcon Launches $50 Million Venture Capital Fund
Pharmaceutical leader partners with Touchdown Ventures to fund promising startups
NEWS PROVIDED BYColorcon Ventures Inc
Sep 18, 2019, 03:25 ET
SHARE THIS ARTICLE
HARLEYSVILLE, Pennsylvania, Sept. 18, 2019 /PRNewswire/ — Colorcon, a world leader in the development, supply and technical support of specialty products for the pharmaceutical industry, today announced the establishment of Colorcon Ventures to invest in promising companies in the pharmaceutical industry. Colorcon’s business focus is on advanced coating systems, modified release technologies and functional excipients for use in pharmaceutical immediate and modified release dosage forms.
Colorcon Ventures is a $50 million venture fund focused on startups that are strategically relevant to the core Colorcon business. The fund will target investments in transformational solutions across manufacturing, supply chain, and delivery of pharmaceutical products and services. The fund is not investing in companies developing active ingredients or molecules.
The fund will be stage-agnostic, with an emphasis on early and mid-stage companies that demonstrate product market fit and revenue growth. Colorcon Ventures will invest in startups where Colorcon can add value in the form of subject matter expertise or commercial relationships, and leverage Colorcon’s global reach, relationships within the pharmaceutical industry, and agile R&D approach.
“We are excited to launch this venture fund to support the growth of startup companies in the pharmaceutical and healthcare industries,” said Martti Hedman, CEO of Colorcon. “Colorcon has a rich history of innovation and we believe this fund will allow us to continue to serve our customers by partnering with startups.”
Touchdown Ventures, a firm specializing in corporate venture capital, will help manage the Colorcon Ventures fund. Touchdown will work closely with senior executives of Colorcon in all aspects of operating the fund.
“The promise of corporate venture capital is to bring more than just money to the table. A successful corporate investor can generate meaningful value by facilitating commercial relationships with its portfolio companies. We believe that Colorcon Ventures, through close association to the senior executive and business units of Colorcon, is well poised to accomplish this goal,” said David Horowitz, CEO of Touchdown.
For more information about Colorcon Ventures, please visit www.colorconventures.com
Colorcon is a world leader in the development, supply and technical support of specialty ingredients; formulated film coating systems, modified release technologies, and functional excipients for the pharmaceutical industry. Our best-in-class products and technologies are complemented by our extensive application data and value-added services to support all phases of solid oral dose design, development and manufacture.
With focus on market issues and technology development has earned Colorcon an international reputation as a pharmaceutical supplier of choice. That reputation is based on superior product quality, unparalleled technical support, extensive regulatory assistance and reliable supply from multiple locations.
Colorcon has 11 manufacturing facilities, 21 technical service laboratories globally and more than 1200 employees exclusively dedicated to its customer base. For more information, visit www.colorcon.com
About Touchdown Ventures
Touchdown Ventures partners with corporations to manage their venture capital programs. Touchdown works closely with each corporation to achieve the financial and strategic benefits from venture capital investments. The firm maintains offices in Los Angeles, Philadelphia, and San Francisco. More information on Touchdown can be found at www.touchdownvc.com
Corporate Communications Contact:
Deborah J. Taylor
Richard Hayhurst Associates, Ltd.
SOURCE Colorcon Ventures Inc
Copyright © 2019 PR Newswire Association LLC. All Rights Reserved. A Cision company.
Philly startup Oncora Medical received an investment of an undisclosed amount from Varian. and has joined in a strategic partnership between the two, it was announced Friday. The partnership’s goal is to accelerate the development of software tools to enable precision medicine in radiation oncology.
Varian Medical Systems (NYSE: VAR), based in Palo Alto, combines radiation technology with intelligent software tools to attack, reduce and cure cancer. Varian had revenue of $826 million and net income of $29.4 million in its latest quarter ending in June. It has a market cap of nearly $11 billion.
Oncora Medical, Inc. has developed a predictive analytics platform for oncology, capable of analyzing diverse healthcare data and applying advanced machine learning techniques to produce valuable clinical insights.
An important benchmark in Oncora’s development was its joint study, begun in 2017, with University of Texas MD Anderson Cancer Center in Houston to help radiation oncologists develop personalized treatment plans with the goal of improving outcomes.
CEO David Lindsay (Penn) and CTO Chris Berlind, PhD co-founded Oncora Medical in 2014. Gary Kurtzman, MD of Safeguard Scientifics is Board Chairman.
Its raised $2.6 million prior to Varian’s investment, according to SEC filings. iSeed Ventures, DreamIT Ventures and Dorm Room are among the investors.
New Enterprise Associates (commonly referred to as NEA) was once the largest venture capital firm in the world, and is still right near the top with $20 billion in assets under management. NEA launched its newest (and eventually largest) fund this spring, with a target of $3.6 billion. Curalate is a Philly company in its portfolio; larger examples are Uber, and Workday. NEA is equally as powerful on the life sciences side.
NEA profiles today as a large Silicon Valley VC with a strong east coast presence. But if you haven’t been around for awhile, you may not realize it was Baltimore born & bred, a product of an innovative investment management ecosystem including T Rowe Price and Alex Brown.
But in early June 2009, Louis Citron, the general counsel of New Enterprise Associates on St. Paul Street, sent an email to Baltimore Mayor Sheila Dixon announcing NEA was leaving Baltimore. This was not like the Irsays leaving town in the middle of the night for a new stadium in Indy.
In the email, Citron told the mayor the firm is moving to the suburbs because their employees no longer feel safe in the city. “We had people held up at gunpoint,” Citron said. “A number of us have had our cars broken into, and it’s very expensive to get them repaired.” In the e-mail, he noted the “recent local beatings by roving teenagers during the day in this neighborhood, the raucous club in the basement of the Belvedere and other gang violence throughout the city.” NEA worried about the safety of clients visiting the office.
NEA might have eventually left anyway, though its east coast headquarters is now in DC. But its hard to lose economic gems like that and remain viable as a business center.
California-based Veeva Systems was showing some of its Philadelphia ties this week, hosting a major conference in the city. The 2019 Veeva R&D Summit took place Sept. 8-10, 2019 in Philadelphia, and was expected to draw 1,700 life sciences professionals and industry experts. Former Novartis CEO Joe Jimenez and Lilly’s Drug Development leader were featured keynote speakers.
While Silicon Valley is Veeva’s base for managing one of the most sophisticated cloud operations around, it needs to stay close to its major customers on the east coast, as it does through its Radnor office. The R&D summit focused on Veeva’ clinical data side, as Veeva Vault now makes up a majority of its revenues.
Veeva has achieved an important financial milestone in the 2nd calendar quarter of 2019, reporting revenue of $267 million (up 27.3 year over year), assuring a billion dollar run rate for its 2020 fiscal year ending this coming January. Veeva is forecasting total revenues between $1,062 and $1,065 million and non-GAAP operating income between $401 and $404 million for FY 2020.
Veeva says that the number of Vault CTMS customers has doubled in less than a year to 50 (see my earlier article, Veeva Vault has traction in CTMS). Veeeva, among others, is trying to redefine the CTMS category, which is a critical bottleneck in the industry’s need to get products to market in a safe and timely manner.
Veeva also announced today that it will host a 2020 Medical Device & Diagnostics Summit June 1-2, 2020 in Minneapolis, reflecting an increased focus on that segment.
Veeva (NYSE: VEEV) has continued a remarkable stretch of market and financial performance. It currently has a Price/Sales (not P/E) ratio of 21, and its shares have risen almost 80% during 2019.
“The life sciences industry is transforming to precision medicine and software is transforming along with it to the cloud,” CEO Peter Gassner, who was an executive at Salesforce.com Inc. and Peoplesoft Inc. before co-founding Veeva in 2007, recently told Bloomberg. “The stars are aligning.”